Skip to main content
OpenTrials
Completed

NCT Number: NCT02265549

Radiomics for Prediction of Long Term Survival and Local Failure After Stereotactic Radiotherapy for Brain Metastases

Published prognostic scores have limitations in prediction of long term survival after stereotactic radiotherapy for brain metastases. Moreover, no validated tools are available for prediction of local failure. The value of radiomics is evaluated in this perspective.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Metastases, Neoplasm Neoplasm Metastasis Neoplasms Neoplastic Processes Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Maastro Clinic

Maastricht, 6229 ET, Netherlands

About this study

Sensitivity is low for prediction of long term survival of currently available prognostic scores for brain metastases. First the current clinical models will be optimized with a new prognostic model and nomogram. Radiomics is a tool to analyze tumor characteristics based on CT and MR images. These tumor characteristics may reflect tumor biology and outcome. Therefore it is investigated if radiomics improves prediction of long term survival after stereotactic radiotherapy for brain metastases. Moreover, the predictive value of radiomics for local failure is investigated.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Cerebral metastasized patients

Exclusion criteria

-

Treatment and study plan

Primary outcomes

  1. Sensitive value of 12 months survival after stereotactic radiotherapy for brain metastases with radiomics

    Time frame: 1 year

    Sensitivity of 12 months survival after stereotactic radiotherapy for brain metastases with radiomics. Radiomics is a tool to analyze tumor characteristics based on CT and MR images.

  2. Sensitive value of 12 months local failure after stereotactic radiotherapy for brain metastases with radiomics

    Time frame: 1 year

    Sensitivity of 12 months local failure after stereotactic radiotherapy for brain metastases with radiomics. Radiomics is a tool to analyze tumor characteristics based on CT and MR images.

Secondary outcomes

  1. Specificity of 12 months survival and local failure after stereotactic radiotherapy for brain metastases with radiomics.

    Time frame: 1 year

    Specificity of 12 months survival and local failure after stereotactic radiotherapy for brain metastases with radiomics.

  2. Positive predictive value of 12 months survival and local failure after stereotactic radiotherapy for brain metastases with radiomics.

    Time frame: 1 year

    Positive predictive value of 12 months survival and local failure after stereotactic radiotherapy for brain metastases with radiomics.

  3. Negative predictive value of 12 months survival and local failure after stereotactic radiotherapy for brain metastases with radiomics.

    Time frame: 1 year

    Negative predictive value of 12 months survival and local failure after stereotactic radiotherapy for brain metastases with radiomics.

Other outcomes

  1. Area under the curve of published prognostic scores

    Time frame: 1 year

    Area under the curve published prognostic scores

  2. Mismatch rate of published prognostic scores

    Time frame: 1 year

    Mismatch rate of published prognostic scores

Sponsors and collaborators

Lead sponsor

Maastricht Radiation Oncology

Other

Registry information

Official study title

Value of Radiomics for the Prediction of Long Term Survival and Local Failure After Stereotactic Radiotherapy (SRT) for Brain Metastases

Important dates

Study start
2014
Primary completion
2014
Study completion
2014
First posted
Oct 16, 2014
Registry last updated
Jan 26, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.